{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:40:09Z","timestamp":1762540809502,"version":"3.40.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatorenal syndrome (HRS) is a fatal complication of renal dysfunction associated with ascites, liver failure and advanced cirrhosis. Although the best option for long-term survival is liver transplantation, in the critical acute phase, vasoconstrictors are considered first-line supportive agents. Terlipressin is the most widely used vasoconstrictor globally but owing to its short elimination half-life, it is usually administered six hourly by slow intravenous bolus injection. This requires patients to remain in hospital, increasing hospital bed costs and affecting their quality of life. An alternative option for administration of terlipressin is as a continuous infusion using an elastomeric infusor device in the patient\u2019s home. However, stability data on terlipressin in elastomeric infusor devices is lacking. This research aimed to evaluate the stability of terlipressin reconstituted in infusor devices for up to 7\u00a0days at 2\u20138\u00a0\u00b0C and subsequently at 22.5\u00a0\u00b0C for 24\u00a0h, to mimic home storage and administration temperatures. We report that terlipressin was physically and chemically stable under these conditions; all reconstituted infusor concentrations retained above 90% of the original concentration over the test conditions. No colour change or precipitation in the solutions were evident.<\/jats:p>","DOI":"10.1038\/s41598-020-78044-4","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T11:04:47Z","timestamp":1606993487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["An investigation of reconstituted terlipressin infusion stability for use in hepatorenal syndrome"],"prefix":"10.1038","volume":"10","author":[{"given":"Thi Ngoc Nhieu","family":"Bui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su","family":"Sandar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9719-7123","authenticated-orcid":false,"given":"Giuseppe","family":"Luna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Beaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6214-995X","authenticated-orcid":false,"given":"Bruce","family":"Sunderland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7212-0667","authenticated-orcid":false,"given":"Petra","family":"Czarniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"issue":"6","key":"78044_CR1","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1053\/j.ajkd.2011.12.032","volume":"59","author":"C Fagundes","year":"2012","unstructured":"Fagundes, C. & Gin\u00e8s, P. Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis. Am. J. Kidney Dis. 59(6), 874\u2013885 (2012).","journal-title":"Am. J. Kidney Dis."},{"key":"78044_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005162.pub4","author":"AS Allegretti","year":"2017","unstructured":"Allegretti, A. S. et al. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD005162.pub4 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"78044_CR3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1080\/03007995.2018.1552575","volume":"35","author":"J Zhang","year":"2019","unstructured":"Zhang, J. et al. Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence. Curr. Med. Res. Opin. 35(5), 859\u2013868 (2019).","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"78044_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/17474124.2018.1417034","volume":"12","author":"I Colle","year":"2018","unstructured":"Colle, I. & Laterre, P. F. Hepatorenal syndrome: the clinical impact of vasoactive therapy. Expert Rev. Gastroenterol. 12(2), 173\u2013188 (2018).","journal-title":"Expert Rev. Gastroenterol."},{"issue":"16","key":"78044_CR5","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1097\/MD.0000000000010431","volume":"97","author":"H Wang","year":"2018","unstructured":"Wang, H., Liu, A., Bo, W., Feng, X. & Hu, Y. Terlipressin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. Medicine. 97(16), e431. https:\/\/doi.org\/10.1097\/MD.0000000000010431 (2018).","journal-title":"Medicine."},{"issue":"2","key":"78044_CR6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/hep.27709","volume":"62","author":"M Cavallin","year":"2015","unstructured":"Cavallin, M. et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology 62(2), 567\u2013574 (2015).","journal-title":"Hepatology"},{"issue":"3","key":"78044_CR7","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","volume":"53","author":"S Neri","year":"2008","unstructured":"Neri, S. et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig. Dis. Sci. 53(3), 830\u2013835 (2008).","journal-title":"Dig. Dis. Sci."},{"issue":"5","key":"78044_CR8","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","volume":"134","author":"AJ Sanyal","year":"2008","unstructured":"Sanyal, A. J. et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134(5), 1360\u20131368 (2008).","journal-title":"Gastroenterology"},{"key":"78044_CR9","first-page":"1946","volume":"12","author":"FN Silawat","year":"2011","unstructured":"Silawat, F. N. et al. Efficacy of terlipressin and albumin in the treatment of hepatorenal syndrome. World Appl. Sci. J. 12, 1946\u20131950 (2011).","journal-title":"World Appl. Sci. J."},{"issue":"7","key":"78044_CR10","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","volume":"150","author":"TD Boyer","year":"2016","unstructured":"Boyer, T. D. et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology 150(7), 1579-1589.e2 (2016).","journal-title":"Gastroenterology"},{"key":"78044_CR11","unstructured":"Ferring Pharmaceuticals. Terlipressin (Glypressin). MIMS Online. 2020. Available from: https:\/\/www-mimsonline-com-au.dbgw.lis.curtin.edu.au\/Search\/FullPI.aspx?ModuleName=Product%20Info&searchKeyword=Glypressin&PreviousPage=~\/Search\/QuickSearch.aspx&SearchType=&ID=94940001_2. Accessed 11 Nov 2020."},{"issue":"4","key":"78044_CR12","first-page":"134","volume":"8","author":"A Sharman","year":"2008","unstructured":"Sharman, A. & Low, J. Vasopressin and its role in critical care. CEACCP 8(4), 134\u2013137 (2008).","journal-title":"CEACCP"},{"issue":"3","key":"78044_CR13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/jgh.14009","volume":"33","author":"T Papaluca","year":"2018","unstructured":"Papaluca, T. & Gow, P. Terlipressin: current and emerging indications in chronic liver disease. J. Gastroenterol. Hepatol. 33(3), 591\u2013598 (2018).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"78044_CR14","unstructured":"Mallinckrodt Pharmaceuticals. Terlipressin (Lucassin). MIMS Online. 2020. Available from: https:\/\/www-mimsonline-com-au.dbgw.lis.curtin.edu.au\/Search\/FullPI.aspx?ModuleName=Product%20Info&searchKeyword=lucassin&PreviousPage=~\/Search\/QuickSearch.aspx&SearchType=&ID=97550001_2. Accessed 11 Nov 2020."},{"issue":"3","key":"78044_CR15","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/hep.28396","volume":"63","author":"M Cavallin","year":"2016","unstructured":"Cavallin, M. et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology 63(3), 983\u2013992 (2016).","journal-title":"Hepatology"},{"key":"78044_CR16","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.2147\/DDDT.S212052","volume":"13","author":"F Foy","year":"2019","unstructured":"Foy, F. et al. An investigation of the stability of meropenem in elastomeric infusion devices. Drug Des. Dev. Ther. 13, 2655 (2019).","journal-title":"Drug Des. Dev. Ther."},{"key":"78044_CR17","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). British Pharmacopoeia. Monographs: medicinal and pharmaceutical substances\/erlipressin. In: London: The Stationary Office. Available from: https:\/\/www-pharmacopoeia-com.dbgw.lis.curtin.edu.au\/bp-2019\/monographs\/terlipressin.html?date=2019-07-01&text=terlipressin. Accessed 19 Jul 2019 (2019)."},{"issue":"6","key":"78044_CR18","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/hep.27154","volume":"60","author":"M Robertson","year":"2014","unstructured":"Robertson, M. et al. Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation. Hepatology 60(6), 2125\u20132126 (2014).","journal-title":"Hepatology"},{"issue":"3","key":"78044_CR19","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1053\/j.gastro.2009.03.064","volume":"137","author":"AL Gerbes","year":"2009","unstructured":"Gerbes, A. L., Huber, E. & G\u00fclberg, V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to iv bolus administration. Gastroenterology 137(3), 1179 (2009).","journal-title":"Gastroenterology"},{"issue":"6","key":"78044_CR20","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1097\/CCM.0b013e3182120842","volume":"39","author":"A Mukhtar","year":"2011","unstructured":"Mukhtar, A. et al. The use of terlipressin during living donor liver transplantation: effects on systemic and splanchnic hemodynamics and renal function. Crit. Care Med. 39(6), 1329\u20131334 (2011).","journal-title":"Crit. Care Med."},{"issue":"4","key":"78044_CR21","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s11095-009-0045-6","volume":"27","author":"MC Manning","year":"2010","unstructured":"Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W. & Katayama, D. S. Stability of protein pharmaceuticals: an update. Pharm. Res. 27(4), 544\u2013575 (2010).","journal-title":"Pharm. Res."},{"issue":"3","key":"78044_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","volume":"4","author":"M Blessy","year":"2014","unstructured":"Blessy, M., Patel, R. D., Prajapati, P. N. & Agrawal, Y. Development of forced degradation and stability indicating studies of drugs\u2014a review. J. Pharm. Sci. Anal. 4(3), 159\u2013165 (2014).","journal-title":"J. Pharm. Sci. Anal."},{"issue":"3","key":"78044_CR23","first-page":"424","volume":"2","author":"PM Kumar","year":"2010","unstructured":"Kumar, P. M. & Sreeramulu, J. Stability indicating RP-HPLC method for simultaneous determination of terlipressin in pure and pharmaceutical formulation. J. Chem. Pharm. Res. 2(3), 424\u2013432 (2010).","journal-title":"J. Chem. Pharm. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78044-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78044-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78044-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:16:03Z","timestamp":1670372163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78044-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["78044"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-78044-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2020,12,3]]},"assertion":[{"value":"11 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21037"}}